BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35933911)

  • 21. Hypereosinophilic disorders.
    Ogbogu PU; Klion AD
    J Allergy Clin Immunol Pract; 2015; 3(2):304-5; quiz 306. PubMed ID: 25754721
    [No Abstract]   [Full Text] [Related]  

  • 22. Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib.
    Kim DS; Lee S; Choi CW
    Korean J Intern Med; 2018 May; 33(3):642-644. PubMed ID: 28651427
    [No Abstract]   [Full Text] [Related]  

  • 23. FIP1L1-PDGFRA-Associated Hypereosinophilic Syndrome as a Treatable Cause of Watershed Infarction.
    Tennenbaum J; Groh M; Venditti L; Campos-Gazeau F; Chalayer E; De Broucker T; Hamidou M; Hunault M; Lyoubi A; Meunier R; Muron T; Sène D; Slama B; Guidoux C; Lefèvre G; Kahn JE; Denier C; Rohmer J
    Stroke; 2021 Oct; 52(10):e605-e609. PubMed ID: 34304603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].
    Li B; Zhang GS; Dai CW; Pei MF
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):448-52. PubMed ID: 15854548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of Hypereosinophilic Syndromes.
    Roufosse F
    Immunol Allergy Clin North Am; 2015 Aug; 35(3):561-75. PubMed ID: 26209900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exquisite response to imatinib mesylate in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome: a 12-year experience of the Polish Hypereosinophilic Syndrome Study Group.
    Helbig G; Lewandowski K; Świderska A; Rodzaj M; Seferyńska I; Gajkowska-Kulik J
    Pol Arch Intern Med; 2020 Mar; 130(3):255-257. PubMed ID: 32125294
    [No Abstract]   [Full Text] [Related]  

  • 27. [Disorders with eosinophilia, treatment of hypereosinophilic syndrome].
    Borbényi Z
    Orv Hetil; 2005 May; 146(18 Suppl 1):911-6. PubMed ID: 15921304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study.
    Helbig G; Moskwa A; Hus M; Piszcz J; Swiderska A; Urbanowicz A; Całbecka M; Gajkowska J; Seferyńska I; Hałasz M; Woszczyk D; Markiewicz M; Krzemień S
    Hematol Oncol; 2010 Jun; 28(2):93-7. PubMed ID: 19728396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
    Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
    Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.
    Roche-Lestienne C; Lepers S; Soenen-Cornu V; Kahn JE; Laï JL; Hachulla E; Drupt F; Demarty AL; Roumier AS; Gardembas M; Dib M; Philippe N; Cambier N; Barete S; Libersa C; Bletry O; Hatron PY; Quesnel B; Rose C; Maloum K; Blanchet O; Fenaux P; Prin L; Preudhomme C
    Leukemia; 2005 May; 19(5):792-8. PubMed ID: 15772698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Durable efficacity and remission after treatment with imatinib mesylate for FIP1L1-PDGFRA transcript negative associated eosinophilic cardiomyopathy].
    Sekkach Y; Mekouar F; Jira M; Elqatni M; Elomri N; Fatihi J; Badaoui M; Hammi S; Smaali J; El Khattabi A; Amezyane T; Abouzahir A; Ghafir D
    Ann Pharm Fr; 2011 Sep; 69(5):277-81. PubMed ID: 21924129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generalized Eruptive Histiocytosis Associated With FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia.
    Ziegler B; Peitsch WK; Reiter A; Marx A; Goerdt S; Géraud C
    JAMA Dermatol; 2015 Jul; 151(7):766-9. PubMed ID: 25923837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy.
    Chalmers ZR; Ali SM; Ohgami RS; Campregher PV; Frampton GM; Yelensky R; Elvin JA; Palma NA; Erlich R; Vergilio JA; Chmielecki J; Ross JS; Stephens PJ; Hermann R; Miller VA; Miles CR
    Blood Cancer J; 2015 Feb; 5(2):e278. PubMed ID: 25658984
    [No Abstract]   [Full Text] [Related]  

  • 34. False-Negative Testing for FIP1L1::PDGFRA by Fluorescence in situ Hybridization Is a Frequent Cause of Diagnostic Delay.
    Pongdee T; Berry A; Wetzler L; Sun X; Thumm L; Yoon P; Kuang FL; Makiya M; Constantine G; Khoury P; Rheinbay E; Lane AA; Maric I; Klion AD
    Acta Haematol; 2023; 146(4):316-321. PubMed ID: 37285821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Synchronous detection of T-cell clonality and FIP1L1-PDGFRA fusion gene in a hypereosinophilic syndrome].
    Martinaud C; Souraud JB; Cournac JM; Pons S; Ménard G; de Jaureguiberry JP; Brisou P
    Rev Med Interne; 2011 May; 32(5):e66-8. PubMed ID: 20633965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endomyocardial Fibrosis With End-Stage Heart Failure as a Consequence of a Myeloproliferative Neoplasm With Hypereosinophilia.
    Strong C; Abecasis J; Afonso C; Trabulo M; Gouveia R
    Can J Cardiol; 2018 Sep; 34(9):1233.e13-1233.e15. PubMed ID: 30170680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FIP1L1-PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement.
    Williams C; Kalra S; Nath U; Bown N; Wilson V; Wilkins BS; Neylon AJ
    J Clin Pathol; 2008 May; 61(5):677-80. PubMed ID: 18256119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel FOXP1-PDGFRA fusion gene in myeloproliferative neoplasm with eosinophilia.
    Sugimoto Y; Sada A; Shimokariya Y; Monma F; Ohishi K; Masuya M; Nobori T; Matsui T; Katayama N
    Cancer Genet; 2015 Oct; 208(10):508-12. PubMed ID: 26319757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [FIP1L1-PDGFRalpha-positive myeloproliferative disease with hypereosinophilia: clinical characteristics and pathogenetic therapy].
    Nemchenko IS; Khoroshko ND; Turkina AG; Sokolova MA; Kokhno AV; Semenova EA; Zakharova AV
    Ter Arkh; 2005; 77(7):90-2. PubMed ID: 16116920
    [No Abstract]   [Full Text] [Related]  

  • 40. Two cases with hypereosinophilic syndrome shown with real-time PCR and responding well to imatinib treatment.
    Selvi N; Kaymaz BT; Sahin HH; Pehlivan M; Aktan C; Dalmızrak A; Inalpolat E; Kosova B; Yılmaz M; Okan V; Saydam G
    Mol Biol Rep; 2013 Feb; 40(2):1591-7. PubMed ID: 23076533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.